Skip to content
Tagged COVID-19 Biotechnology SARS-CoV-2 Life Science cancer CORONAVIRUS pandemic
BioXone

BioXone

rethinking future

August 7, 2026
  • About
  • BiotechTodayNews
    • IndiaWeekly Biotech News of India
    • WorldWeekly Biotech News of The World
  • DNA-TalesArticles
    • BiotechnopediaInteresting articles written by BioXone members and associates.
    • Scientists’ CornerArticles from the pioneers of Biotechnology.
    • Cellular CommunicationInterview of greatest researchers’ in the field.
  • Myth-LysisFact Check
  • Signalling PathwayCareer related updates
    • ExaminationsExamination related articles.
    • Job and InternshipJobs and Internship related articles.
  • Courses
  • Contact

Most Viewed This Week

July 13, 2026July 13, 2026

Why Do We Age? The Biology Of Ageing Explained

1
October 17, 2023October 16, 2023

The Corrosion Prediction from the Corrosion Product Performance

2
October 1, 2023September 30, 2023

Nitrogen Resilience in Waterlogged Soybean plants

3
September 28, 2023September 28, 2023

Cell Senescence in Type II Diabetes: Therapeutic Potential

4
September 26, 2023September 25, 2023

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

5
September 25, 2023September 25, 2023

AI Literacy in Early Childhood Education: Challenges and Opportunities

6

Search Field

Subscribe Now

  • Home
  • BiotechToday
  • PLASMA THERAPY – DEAD END FOR COVID-19?

Ferrero Rocher Food Technology Executive Recruitment | Apply Online

Legume has the power to restore damaged lands

PLASMA THERAPY – DEAD END FOR COVID-19?
  • BiotechToday
  • India

PLASMA THERAPY – DEAD END FOR COVID-19?

bioxone October 29, 2020October 29, 2020

Aishila Kar, Amity University Kolkata

In New Delhi, since ILBS Hospital, initiates its plasma bank from July, requests have poured in continuously. Jai Prakash said that when someone close to you is about to die, you will take whatever form of hope you can find, age of 44, who obtained plasma last month for his mother at RML Hospital in Delhi. The plasma gave by those who got better from COVID, and which is theoretically devoted to anti-COVID antibodies, did not save his mother’s life. The complications finally claimed his mother’s life.

Many examples of unfavourable reactions and the incapability of plasma treatment to decrease the number of COVID mortality have been recorded in the ICMR’s PLACID trial. This is the largest trials of plasma therapy in the country, conducted public and private hospitals across India to understand the effectiveness of plasma therapy in the treatment of COVID-19. A total of 464 participants, all with moderate cases, were listed in the study. As a result, the ICMR has declared the possibility of removing plasma therapy as one of the treatments recommended in India’s clinical management for COVID-19. Dr J.C Passey said that every case of COVID-19 is different, and treatment is devised accordingly.

ICMR study noted that the PLACID trial results indicate that there was no difference in 28-day mortality to severe disease among moderately ill COVID-19 patients treated with plasma along with the best standard of care compared to the best standard of care alone. But, even as the government pulling back on plasma treatment, most doctors do not consider it to be a huge setback to the treatment.

Drugs like Remdesivir and HCQ (Hydroxychloroquine) are much more in use than plasma. The larger concern remains if the government will also remove Remdesivir and HCQ from the guidelines after the WHO solidarity trials registered them to be ineffective in the decrease of COVID mortality. With many hospitals having invested notably in procuring these medicines, the loss would be far greater than that of plasma.

Also read: One-pot Visual RT PCR as a diagnostic test for SARS-CoV-2

SOURCE- The plasma dead end?    | India Today Insight

https://www.indiatoday.in/india-today-insight/story/the-plasma-dead-end-1734979-2020-10-25

  • Why Do We Age? The Biology Of Ageing Explained
  • The Corrosion Prediction from the Corrosion Product Performance
  • Nitrogen Resilience in Waterlogged Soybean plants
  • Cell Senescence in Type II Diabetes: Therapeutic Potential
  • Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Related

Tagged Anti COVID Antibodies Clinical Management Covid covid 19 COVID in the world COVID news today covid treatment Covid vaccine drugs ICMR Medicine New Delhi patients PLACID trial Plasma Bank Plasma therapy Public Hospital SARS-CoV-2

2 thoughts on “PLASMA THERAPY – DEAD END FOR COVID-19?”

  1. Pingback: Legume has the power to restore damaged lands - BioXone
  2. Pingback: Early Response to Influenza Virus in Dendritic Cells - BioXone

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Next Post
  • BiotechToday
  • World

Legume has the power to restore damaged lands

bioxone October 29, 2020

Sristi Raj Rai, Amity University Kolkata Habitable dry land is mainly the playing field on earth for maximum human activities that have occurred to date and that might take place. These activities require energy and production of it requires the consumption of a balanced diet. To fulfill the above-mentioned necessities, one must have accessible fertile […]

Legume

Related Post

  • BiotechToday
  • World

Proteome plasticity at high temperatures!

BioTech Today July 25, 2021July 24, 2021

Esha Mukherjee, Amity University Noida By changing the form, location, and function of several of their proteins, common yeast can adapt and survive in response to a long-term change in temperature. The startling findings highlight protein plasticity at the molecular and conformational levels. It demonstrates the ability of molecular biology in understanding organismal responses to […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

Multisystem Inflammatory Syndrome may develop due to Covid

BioTech Today June 26, 2021June 25, 2021

Ananya Ghosal, MAKAUT(WB) In the SARS-CoV-2 pandemic, new information is showing us the path of the disease. Multisystem Inflammatory Syndrome (MIS) is an example of a complication that is also described as a hyper-inflammatory syndrome, where the characteristics are the same as Kawasaki disease. From the publication of CDC, 27 adult cases were reported which […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

Lambda Variant of SARS COVID-19 identified: More contagious & deadly

BioTech Today July 8, 2021July 8, 2021

Shreyas bhat, DY Patil School of biotechnology and bioinformatics A new and more contagious variant of SARS COVID-19 was announced by the world health organization (WHO). According to some reports, the new lambda variant is associated with community transmission in more than 30 countries, with a substantial rise in cases over time. It is also […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Breaking News

Why Do We Age? The Biology Of Ageing Explained

The Corrosion Prediction from the Corrosion Product Performance

Nitrogen Resilience in Waterlogged Soybean plants

Cell Senescence in Type II Diabetes: Therapeutic Potential

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

AI Literacy in Early Childhood Education: Challenges and Opportunities

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

Terms and Conditions
Shipping and Delivery Policy
Cancellation and Refund Policy
Contact Us
Privacy Policy